Interleukin-1 receptor antagonist, soluble tumor necrosis factor-a receptor type I and II and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-β1a

Paola Perini, Michela Tiberio, Susanna Sivieri, Antonella Facchinetti, Giovanni Biasi, Paolo Gallo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: interferon beta (IFN-β) reduces relapse rate and disease progression in patients with the relapsing-remitting form of multiple sclerosis (RRMS). IFN-β may act by upregulating the expression of anti-inflammatory components of the immune system. Objectives: To determine whether weekly intramuscular (i.m.) injection of IFN-β1a had a short- or long-term effect on the expression of naturally occurring soluble factors that play an immunosuppressive role within the cytokine network. Materials and Methods: serum levels of interleukin-1 receptor antagonist (IL-1Ra), soluble tumor necrosis factor alpha receptor type I and type II (sTNF-αRI and sTNF-αRII), and soluble E-selectin (sE-Sel) were followed over time in ten patients with RRMS who were treated with weekly i.m. injections of 30 μg (= 6 MU) of IFN-β1a. Patient sera were sampled before, and 24, 48, 72, 96, and 168 hours after the first TFN-β1a injection (short-term), and then at 1, 3, 6, 9 and 12 months after therapy initiation (long-term); highly sensitive, commercially available ELISA tests were used. Results: serum levels of IL-1Ra, sTNF-αRI and sTNF-αRII, but not sE-Sel were significantly increased in both short- and long-term follow-up. Interestingly, IL-1Ra, sTNF-αRI and sTNF-αRII behaviors were completely different, suggesting that these naturally occurring immunoregulatory factors were differentially affected by IFN-β1a. Conclusion: our study demonstrates that weekly i.m. injection of 30 μg of IFN-β1a induces the expression of soluble mediators that may suppress the activities of pro-inflammatory cytokines such as IL-1 and TNF-α.

Original languageEnglish
Pages (from-to)81-85
Number of pages5
JournalEuropean Cytokine Network
Volume11
Issue number1
Publication statusPublished - 2000

Fingerprint

Receptors, Tumor Necrosis Factor, Type II
Receptors, Tumor Necrosis Factor, Type I
E-Selectin
Interleukin-1 Receptors
Intramuscular Injections
Interferons
Multiple Sclerosis
Tumor Necrosis Factor-alpha
Relapsing-Remitting Multiple Sclerosis
Interferon-beta
Serum
Cytokines
Immune system
Immunosuppressive Agents
Interleukin-1
Disease Progression
Immune System
Anti-Inflammatory Agents
Enzyme-Linked Immunosorbent Assay
Recurrence

Keywords

  • Interferon beta
  • Interleukin-1 receptor antagonist
  • Multiple sclerosis
  • Soluble E-selectin
  • Soluble tumor necrosis factor alpha receptor

ASJC Scopus subject areas

  • Cell Biology
  • Immunology

Cite this

@article{6ce79ae7caa444998690529dae2f8e46,
title = "Interleukin-1 receptor antagonist, soluble tumor necrosis factor-a receptor type I and II and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-β1a",
abstract = "Background: interferon beta (IFN-β) reduces relapse rate and disease progression in patients with the relapsing-remitting form of multiple sclerosis (RRMS). IFN-β may act by upregulating the expression of anti-inflammatory components of the immune system. Objectives: To determine whether weekly intramuscular (i.m.) injection of IFN-β1a had a short- or long-term effect on the expression of naturally occurring soluble factors that play an immunosuppressive role within the cytokine network. Materials and Methods: serum levels of interleukin-1 receptor antagonist (IL-1Ra), soluble tumor necrosis factor alpha receptor type I and type II (sTNF-αRI and sTNF-αRII), and soluble E-selectin (sE-Sel) were followed over time in ten patients with RRMS who were treated with weekly i.m. injections of 30 μg (= 6 MU) of IFN-β1a. Patient sera were sampled before, and 24, 48, 72, 96, and 168 hours after the first TFN-β1a injection (short-term), and then at 1, 3, 6, 9 and 12 months after therapy initiation (long-term); highly sensitive, commercially available ELISA tests were used. Results: serum levels of IL-1Ra, sTNF-αRI and sTNF-αRII, but not sE-Sel were significantly increased in both short- and long-term follow-up. Interestingly, IL-1Ra, sTNF-αRI and sTNF-αRII behaviors were completely different, suggesting that these naturally occurring immunoregulatory factors were differentially affected by IFN-β1a. Conclusion: our study demonstrates that weekly i.m. injection of 30 μg of IFN-β1a induces the expression of soluble mediators that may suppress the activities of pro-inflammatory cytokines such as IL-1 and TNF-α.",
keywords = "Interferon beta, Interleukin-1 receptor antagonist, Multiple sclerosis, Soluble E-selectin, Soluble tumor necrosis factor alpha receptor",
author = "Paola Perini and Michela Tiberio and Susanna Sivieri and Antonella Facchinetti and Giovanni Biasi and Paolo Gallo",
year = "2000",
language = "English",
volume = "11",
pages = "81--85",
journal = "European Cytokine Network",
issn = "1148-5493",
publisher = "John Libbey Eurotext",
number = "1",

}

TY - JOUR

T1 - Interleukin-1 receptor antagonist, soluble tumor necrosis factor-a receptor type I and II and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-β1a

AU - Perini, Paola

AU - Tiberio, Michela

AU - Sivieri, Susanna

AU - Facchinetti, Antonella

AU - Biasi, Giovanni

AU - Gallo, Paolo

PY - 2000

Y1 - 2000

N2 - Background: interferon beta (IFN-β) reduces relapse rate and disease progression in patients with the relapsing-remitting form of multiple sclerosis (RRMS). IFN-β may act by upregulating the expression of anti-inflammatory components of the immune system. Objectives: To determine whether weekly intramuscular (i.m.) injection of IFN-β1a had a short- or long-term effect on the expression of naturally occurring soluble factors that play an immunosuppressive role within the cytokine network. Materials and Methods: serum levels of interleukin-1 receptor antagonist (IL-1Ra), soluble tumor necrosis factor alpha receptor type I and type II (sTNF-αRI and sTNF-αRII), and soluble E-selectin (sE-Sel) were followed over time in ten patients with RRMS who were treated with weekly i.m. injections of 30 μg (= 6 MU) of IFN-β1a. Patient sera were sampled before, and 24, 48, 72, 96, and 168 hours after the first TFN-β1a injection (short-term), and then at 1, 3, 6, 9 and 12 months after therapy initiation (long-term); highly sensitive, commercially available ELISA tests were used. Results: serum levels of IL-1Ra, sTNF-αRI and sTNF-αRII, but not sE-Sel were significantly increased in both short- and long-term follow-up. Interestingly, IL-1Ra, sTNF-αRI and sTNF-αRII behaviors were completely different, suggesting that these naturally occurring immunoregulatory factors were differentially affected by IFN-β1a. Conclusion: our study demonstrates that weekly i.m. injection of 30 μg of IFN-β1a induces the expression of soluble mediators that may suppress the activities of pro-inflammatory cytokines such as IL-1 and TNF-α.

AB - Background: interferon beta (IFN-β) reduces relapse rate and disease progression in patients with the relapsing-remitting form of multiple sclerosis (RRMS). IFN-β may act by upregulating the expression of anti-inflammatory components of the immune system. Objectives: To determine whether weekly intramuscular (i.m.) injection of IFN-β1a had a short- or long-term effect on the expression of naturally occurring soluble factors that play an immunosuppressive role within the cytokine network. Materials and Methods: serum levels of interleukin-1 receptor antagonist (IL-1Ra), soluble tumor necrosis factor alpha receptor type I and type II (sTNF-αRI and sTNF-αRII), and soluble E-selectin (sE-Sel) were followed over time in ten patients with RRMS who were treated with weekly i.m. injections of 30 μg (= 6 MU) of IFN-β1a. Patient sera were sampled before, and 24, 48, 72, 96, and 168 hours after the first TFN-β1a injection (short-term), and then at 1, 3, 6, 9 and 12 months after therapy initiation (long-term); highly sensitive, commercially available ELISA tests were used. Results: serum levels of IL-1Ra, sTNF-αRI and sTNF-αRII, but not sE-Sel were significantly increased in both short- and long-term follow-up. Interestingly, IL-1Ra, sTNF-αRI and sTNF-αRII behaviors were completely different, suggesting that these naturally occurring immunoregulatory factors were differentially affected by IFN-β1a. Conclusion: our study demonstrates that weekly i.m. injection of 30 μg of IFN-β1a induces the expression of soluble mediators that may suppress the activities of pro-inflammatory cytokines such as IL-1 and TNF-α.

KW - Interferon beta

KW - Interleukin-1 receptor antagonist

KW - Multiple sclerosis

KW - Soluble E-selectin

KW - Soluble tumor necrosis factor alpha receptor

UR - http://www.scopus.com/inward/record.url?scp=0842278239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842278239&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 81

EP - 85

JO - European Cytokine Network

JF - European Cytokine Network

SN - 1148-5493

IS - 1

ER -